宣泰医药(688247.SH)：熊去氧胆酸胶囊拟中选国家药品接续采购

Core Viewpoint - Xuantai Pharmaceutical (688247.SH) has announced its participation in the national organized procurement for the continuation of products whose agreements have expired, with its product, ursodeoxycholic acid capsules, being proposed for selection in this procurement process [1] Group 1: Procurement Participation - The company is involved in the national organized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products [1] - The selection is expected to increase the company's market share and enhance brand influence, positively impacting future operating performance [1]